Aquinox Pharmaceuticals (AQXP) Trading Up 14.3%
Shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) were up 14.3% on Friday . The company traded as high as $15.92 and last traded at $15.31. Approximately 554,055 shares changed hands during trading, an increase of 390% from the average daily volume of 113,070 shares. The stock had previously closed at $13.40.
A number of analysts have recently weighed in on AQXP shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $28.00 price target on shares of Aquinox Pharmaceuticals in a report on Thursday, November 9th. Needham & Company LLC reissued a “buy” rating and issued a $25.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Canaccord Genuity reissued a “buy” rating and issued a $22.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Tuesday, November 21st. Zacks Investment Research raised shares of Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Tuesday, January 9th. Finally, BidaskClub raised shares of Aquinox Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, February 5th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $22.80.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.12. research analysts anticipate that Aquinox Pharmaceuticals Inc will post -2.08 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Aquinox Pharmaceuticals (AQXP) Trading Up 14.3%” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/02/11/aquinox-pharmaceuticals-aqxp-trading-up-14-3.html.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.